Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 2
2009 3
2011 1
2012 1
2016 2
2020 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Primary Retroperitoneal Cystoadenocarcinoma: A Systematic Review.
Pellegrino B, Sikokis A, Bersanelli M, Leonetti A, Leonardi F, Di Meglio G, Buti S. Pellegrino B, et al. Among authors: di meglio g. Gynecol Obstet Invest. 2016;81(5):385-93. doi: 10.1159/000446954. Epub 2016 Jun 17. Gynecol Obstet Invest. 2016. PMID: 27309542 Review.
Miliary hepatic metastases from neuroendocrine carcinoma.
Fazio N, Di Meglio G, Lorizzo K, de Brand F. Fazio N, et al. Among authors: di meglio g. Dig Surg. 2008;25(5):330. doi: 10.1159/000158907. Epub 2008 Oct 1. Dig Surg. 2008. PMID: 18827485 Free article. No abstract available.
Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer.
Lorizzo K, Fazio N, Radice D, Boselli S, Ariu L, Zampino MG, Nolè F, Magni E, Ardito R, Minchella I, Rocca A, Di Meglio G, Squadroni M, de Braud F. Lorizzo K, et al. Among authors: di meglio g. Cancer Chemother Pharmacol. 2009 Jul;64(2):301-6. doi: 10.1007/s00280-008-0871-y. Epub 2008 Nov 26. Cancer Chemother Pharmacol. 2009. PMID: 19034450
Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol.
Bongiovanni A, Liverani C, Pusceddu S, Leo S, Di Meglio G, Tamberi S, Santini D, Gelsomino F, Pucci F, Berardi R, Lolli I, Bergamo F, Ricci S, Foca F, Severi S, Ibrahim T; SENECA Study Team Investigators. Bongiovanni A, et al. Among authors: di meglio g. BMJ Open. 2020 Jul 19;10(7):e034393. doi: 10.1136/bmjopen-2019-034393. BMJ Open. 2020. PMID: 32690499 Free PMC article.
Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors.
Panzuto F, Campana D, Fazio N, Brizzi MP, Boninsegna L, Nori F, Di Meglio G, Capurso G, Scarpa A, Dogliotti L, De Braud F, Tomassetti P, Delle Fave G, Falconi M. Panzuto F, et al. Among authors: di meglio g. Neuroendocrinology. 2012;96(1):32-40. doi: 10.1159/000334038. Epub 2011 Dec 28. Neuroendocrinology. 2012. PMID: 22205326
Metachronous Colon Metastases from Gastric Adenocarcinoma: A Case Report.
Pace U, Contino G, Chiappa A, Bertani E, Bianchi PP, Fazio N, Renne G, Di Meglio G, Andreoni B. Pace U, et al. Among authors: di meglio g. Case Rep Oncol. 2009 May 26;2(2):92-96. doi: 10.1159/000215945. Case Rep Oncol. 2009. PMID: 20740169 Free PMC article.
12 results